Important Update: Safe Transition to New Rybelsus® (Oral Semaglutide) Formulation in NEL Primary Care
Posted on:
The latest information on the Rybelsus® (oral semaglutide) formulation change is now available. It outlines how to safely initiate and switch to a new, higher bioavailability formulation with different tablet strengths. Please prioritise the safe prescribing and dispensing of the new formulation, especially for patients already prescribed Rybelsus®. Review all affected patients and ensure timely transition before the old version is phased out by at least 31st January 2026.
Further details can be found in the guidance note and regular updates can be found in the NEL Prescribing and Medicines Newsletter.
With thanks and best wishes,
Natasha Natasha Callender
Head of Medicines Optimisation – Safety, Quality and Governance
NHS North East London